Introduction {#Sec1}
============

CD93 is expressed by endothelial cells, cells of myeloid lineage, platelets, and early hematopoietic stem cells and is an important lineage-specific marker of early B-cell developmental stages (Cancro [@CR4]; Danet et al. [@CR7]; Fonseca et al. [@CR12]; Nepomuceno et al. [@CR23]; Nepomuceno and Tenner [@CR22]; Petrenko et al. [@CR26]). Normally, CD93 is expressed at high levels on pro-, pre- and immature bone marrow (BM) B-cell progenitors as well as transitional (TR) B cells in the periphery (Cancro [@CR4]). The *Cd93* gene is located at 84 cM on murine chromosome 2 (Kim et al. [@CR18]) and encodes a type I O-glycosylated transmembrane protein whose domain structure includes an amino-terminal C-type lectin domain, a tandem array of five epidermal growth factor (EGF)-like repeats, a single hydrophobic transmembrane region, and a short cytoplasmic domain that contains a PDZ binding domain and a moesin interaction site (Bohlson et al. [@CR2]; Kim et al. [@CR18]; Norsworthy et al. [@CR24]; Petrenko et al. [@CR26]; Zhang et al. [@CR38]). This domain structure bears a unique resemblance to the selectin family of adhesion molecules (Dean et al. [@CR8]; Kim et al. [@CR18]; Norsworthy et al. [@CR24]; Petrenko et al. [@CR26]; Rosen [@CR31]). Additionally, CD93 is subject to metallo-protease-mediated ecto-domain cleavage or shedding, which is characteristic of several inflammatory mediators and adhesion molecules including TNF-α, TGF-α, TGF-β, EGF, CD44, and L-selectin (Bohlson et al. [@CR2]). Despite its initial identification as a receptor for the C1q component of complement and demonstration of an in vivo kinetic defect in the clearance of apoptotic cells in B6 CD93^−/−^ mice, the exact in vivo function of this molecule is yet to be elucidated.

Here, we identify a point mutation in the NOD *Cd93* gene, which maps to the *Idd13* locus, a region encoding a high degree of penetrance for diabetes susceptibility in non-obese diabetic (NOD) mice (Kim et al. [@CR18]; Serreze et al. [@CR32]). Interestingly, we also identified this *Cd93* polymorphism in NZB/W F1 mice, to which the lupus susceptibility loci, *Wbw1* and *Nkt2*, are tightly linked (Rahman et al. [@CR29]; Esteban et al. [@CR10]). This point mutation is associated with aberrant expression of CD93 on NOD and NZB/W F1 B cells in the pro-/pre-, immature, and TR subsets as compared with non-autoimmune B6 mice. The *Idd13* and *Wbw1* and *Nkt2* loci are known to play a role in the regulation of the invariant natural killer T (iNKT) cell compartment (Chen et al. [@CR5]; Esteban et al. [@CR10]; Jordan et al. [@CR16], Rahman et al. [@CR29]). Since NOD and NZB/W F1 mice are known to have deficiencies in their iNKT cell populations (Baxter et al. [@CR1]; Cain et al. [@CR3]; Chen et al. [@CR5]; Duarte et al. [@CR9]; Esteban et al. [@CR10]; Jordan et al. [@CR16]; Matsuki et al. [@CR20]; Poulton et al. [@CR27]; Rahman et al. [@CR29]; Wagner et al. [@CR36]), we sought to determine whether our finding of a mutation in the NOD and NZB/W F1 *Cd93* gene is linked to regulation of iNKT cells in these autoimmune-prone strains. We assessed the iNKT cell populations in non-autoimmune B6 CD93 knockout (B6 CD93^−/−^) mice and found that they exhibit a profound state of CD4+ iNKT cell deficiency. Moreover, we found that the congenic B6.NOD^Idd13^ mice, which carry the NOD *Cd93* gene, also exhibited this CD4+ iNKT cell deficiency. These findings suggest that *Cd93* may be an important autoimmune susceptibility gene influencing iNKT cell homeostasis.

Materials and methods {#Sec2}
=====================

Mice {#Sec3}
----

C57BL/6J, NOD/ShiLtJ, C3H/HeJ, BALB/cJ, NZBWF1/J, B6.NOD^Idd13-(D2Mit274-D2Mit343)^ (Jax\#3064), NOD.B6^Idd13-(D2Mit490-Ada)^ (Jax\#2346), NOD.B6^Idd13-(Zfp106-Il1a)^ (Jax\#3050), and NOD.B6^Idd13-(Il1a-Pcna)^ (Jax\#3051) mice were obtained from Jackson Laboratories (Bar Harbor, ME). B6 CD93^−/−^ mice, constructed from 129-derived ES cells, were generously donated by Dr. M. Botto and were backcrossed onto the C57BL/6 background for seven generations. All animals used in the described experiments were between 5 and 20 weeks old and were housed in specific pathogen-free conditions at the University of Pennsylvania Medical Center. Animal procedures were in accordance with the Animal Welfare Act.

Abs and flow cytometric analysis {#Sec4}
--------------------------------

The antibodies used in this study were as follows: PerCP conjugated anti-CD45R (B220, RA3-6B2), APC conjugated anti-IgM (II/41), FITC/PE conjugated anti-CD21/35 (7G6), PE conjugated anti-AA4.1, biotinylated 493 mAb (BD Biosciences, San Diego, CA), mAb1696 (R&D systems, Minneapolis, MN), and anti-Rat IgG2b (RG7/11.1) (BD Biosciences). Biotinylated mAb were detected by streptavidin-allophycocyanin (BD Biosciences). PE conjugated CD1d tetramer loaded with PBS-57 (Alpha-galactosyl ceramide (alpha-GalCer) analog) was prepared by the NIH Tetramer Facility. A total of 1--2 × 10^6^ splenocytes, thymocytes, BM, or peripheral blood lymphocytes (PBL) derived cells from age- and sex-matched mice were surface stained in 96-well microtiter plates with various combinations of the previously described antibodies. Preparation and staining of livers was done as previously described (Hammond et al. [@CR15]). Fluorescence-activated cell sorting (FACS) analysis was performed using a FACSCalibur (BD Biosciences, San Jose, CA), and the data were analyzed using FlowJo Software (version 8, Tree Star, Inc, Ashland, OR).

Bone-marrow-derived macrophages {#Sec5}
-------------------------------

Bone-marrow-derived macrophages were prepared from bone marrow progenitors. Briefly, bone marrow was flushed from femurs of 5- or 10-week-old mice and plated in cell culture dishes with Dulbecco's modified Eagle's medium (Invitrogen, San Diego, CA) supplemented with 15% L929 cell-conditioned medium (as a source of macrophage colony-stimulating factor), 10% heat-inactivated fetal calf serum, 100 U/ml penicillin/streptomycin (Invitrogen), and 10 mM HEPES. Additional media was added on day 4, and cells were incubated at 37°C in 5% CO~2~ for 7--8 days until uniform layers of macrophages were established.

sCD93 enzyme-linked immunosorbent assay {#Sec6}
---------------------------------------

Blood was collected by cardiac puncture, placed on ice, centrifuged for 10 min at 3,200 rpm at 4°C, then serum was stored at −70°C until use. Mouse serum was assayed for soluble CD93 using CD93 sandwich enzyme-linked immunosorbent assay (ELISA). Briefly, Immulon 2 HB plates (Thermo Labsystems, Franklin, MA) were coated overnight at 4°C with 2 mcg/ml rat monoclonal anti-mouse CD93 (mAB1696, R&D Systems, Minneapolis, MN) in 0.1 M carbonate buffer, pH 7.4, washed with phosphate buffer saline containing 0.05% Tween-20 (PBST), and blocked with PBST containing 3% dried milk (block buffer) for 1 h. Diluted serum samples were added to wells and incubated for 1 h. After washing with PBST, 1 mcg/ml sheep anti-mouse CD93 antibody (AF1696, R&D Systems) was added to wells for 1 h followed by incubation with anti-sheep horseradish peroxidase-conjugated streptavidin (Jackson, Immunoresearch, West Grove, PA) diluted 1:2,000 in 1% dried milk. Sigma fast *o*-phenylenediamine dihydrochloride peroxidase substrate (Sigma-Aldrich, St. Louis, MO) was added, and the change in absorbance at 405 nm was measured.

Western blot {#Sec7}
------------

Bone-marrow-derived macrophages or B-cell precursors (purified with magnetic activated cell separation using B-cell isolation kit, Miltenyi Biotec, Auburn, CA) were harvested into lysis buffer (50 mM HEPES, pH 7.0, 150 mM NaCl, 10% glycerol, 1.2% Triton X-100, 1.5 mM MgCl~2~, 10 mM sodium pyrophosphate, 100 mM NaF, 1.25 mM sodium orthovanadate, and 1 mM phenylmethylsulfonyl fluoride plus 0.15 U/ml aprotinin, 10 mcg/ml leupeptin, 10 mcg/ml pepstatin A) and incubated on ice for 30 min. After incubation, lysates were centrifuged at 14,000×*g* for 10 min. The supernatants were collected, and protein concentrations were determined using the BCA kit (Pierce Biotechnology, Rockford, IL). Soluble cell extracts were then separated by 8% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidene difluoride (PVDF). The membrane was blocked overnight with 5% dry milk in TBST (0.05% Tween-20 in 20 mM Tris, pH 7.4, 150 mM NaCl). Lysates from bone-marrow-derived macrophages were probed for 2 h at room temperature with polyclonal anti-CD93 cytoplasmic tail Ab 1150 generated against C-terminal 11 aa of CD93 as previously described (Webster et al. [@CR37]) and were washed and probed with secondary horseradish peroxidase conjugate for 1 h at room temperature and developed using ECL (Amersham Biosciences). Lysates from bone-marrow-derived B-cell precursors were incubated overnight with a polyclonal anti-CD93 (Anti-mouse C1qR1, R&D Systems) and probed with secondary anti-sheep antibody.

Polymerase chain reaction amplification and genomic sequencing {#Sec8}
--------------------------------------------------------------

Genomic DNA was isolated from tail snip samples according to standard protocols. The CD93 gene was polymerase chain reaction (PCR) amplified from genomic DNA using primers designed from the published cDNA sequence (NCBI accession number NM_010740.3). The forward oligonucleotide used was 5′-ATGGCCATCTCAACTGGTTT-3′, and the reverse oligonucleotide used was 5′-TCAGCAGTCTGTCCCTGGTG-3′. The PCR product of 1,835 bp, covering the first EGF-like domain of CD93, was isolated on an agarose gel. The bands were cut, and purified DNA was extracted using the QIAGEN QIAquick Gel Extraction kit. Samples were sent for sequencing at the University of Pennsylvania School of Medicine DNA Sequencing Facility.

Statistical analysis {#Sec9}
--------------------

Statistical analysis was performed using the Mann--Whitney test, with differences considered significant at *p* \< 0.05.

Results {#Sec10}
=======

The NOD and NZB/W F1 Cd93 alleles carry an Asn→His polymorphism at amino acid 264 in its first EGF-like domain {#Sec11}
--------------------------------------------------------------------------------------------------------------

Genomic *Cd93* DNA from B6, BALB/c, NOD, and NZB/W F1 mice was PCR amplified and sequenced using various primers to walk along the amplified DNA. A hitherto unidentified coding polymorphism at cDNA nucleotide position 790, which converts AAC→CAC, was discovered in NOD and NZB/W F1 mice (Fig. [1a](#Fig1){ref-type="fig"}). This mutation causes an amino acid substitution from Asn→His at position 264 in the first EGF-like domain of *Cd93* (Fig. [1a](#Fig1){ref-type="fig"}). Fig. 1Identification of a coding polymorphism in the first EGF-like domain of *Cd93* in NOD and NZB/W F1 mice. **a** The *Cd93* gene was PCR amplified from genomic DNA. Sequencing revealed a point mutation at cDNA nucleotide position 790. The AAC→CAC codon change in NOD and NZB/W F1 mice led to an amino acid substitution in the first EGF-like domain of *Cd93* at position 264. The first EGF-like domain in which the defined polymorphism resides is *stippled*. **b** Bone marrow macrophage lysates (*left*) were separated on an 8% SDS-PAGE under reducing conditions, transferred to PVDF, and probed with 5 μg/ml polyclonal anti-CD93 cytoplasmic tail Ab 1150 (*black arrow*). Isolated bone marrow B-cell lysate immunoblots (*right*) were probed with 0.1 μg/ml polyclonal anti-CD93 (anti-C1qR1). The blots were stripped and re-probed for β-actin or β-tubulin to control for similar protein loading. The blots are from one experiment, representative of two, using different animals as a source of bone-marrow-derived macrophages or B cells. **c** sCD93 is detected in sera from NOD and NZB/W F1 mice. Sera were diluted (1:50) and tested for the presence of sCD93 by sandwich ELISA. Shown is the average of triplicate wells (± SD) from one experiment, representative of two, using different animals as a source of sera

CD93 protein is expressed in cell lysates and serum of NOD and NZB/W F1 mice {#Sec12}
----------------------------------------------------------------------------

We next sought to determine whether CD93 protein is expressed in NOD and NZB/W F1 mice. Lysates from in vitro-differentiated, BM-derived macrophages were prepared and used in Western blot. CD93 protein was detected in both NOD and NZB/W F1 lysates as assessed using polyclonal anti-CD93 cytoplasmic tail Ab 1150 (Webster et al. [@CR37]). CD93 bands were seen with NOD and NZB/W F1 mice comparable to the B6 and NOR control strains (Fig. [1b](#Fig1){ref-type="fig"}). Lysates of BM-derived macrophages from the B6 CD93^−/−^ strain (Norsworthy et al. [@CR25]) were used for a negative control. We performed a Western blot on purified BM-derived B-cell precursors to determine whether CD93 protein is detectable on B-cell precursors using a polyclonal anti-CD93 Ab. B-cell lysates from NOD and B6.NOD^Idd13^ mice exhibited a CD93 band similar to B6 counterparts (Fig. [1b](#Fig1){ref-type="fig"}).

CD93 is subject to ecto-domain cleavage by metalloproteinase and, as such, exists in soluble form in vivo (Bohlson et al. [@CR2]). Therefore, as another measure of protein expression, we assessed serum from NOD and NZB/W F1 mice for the presence of sCD93 in an ELISA assay. NOD and NZB/W F1 sera contained measurable levels of sCD93 at a slightly lower concentration compared to B6 sera (Fig. [1c](#Fig1){ref-type="fig"}). sCD93 levels did not change significantly with age. Additionally, the concentration of sCD93 in NOD and NZB/W F1 mice remained constant for up to 30 weeks of age, and no difference was noted between males and females (data not shown).

Surface CD93 expression by pro-/pre-, immature, and transitional B cells is deficient in NOD and NZB/W F1 mice {#Sec13}
--------------------------------------------------------------------------------------------------------------

The expression of CD93 on the various B-cell developmental subsets was characterized using a previously described flow cytometric gating scheme (Cancro [@CR4]; Quinn et al. [@CR28]). In the BM, we resolved the pro-/pre-, immature, and mature recirculating B-cell subsets based on their expression of IgM and B220 (Fig. [2a](#Fig2){ref-type="fig"}). The B220^lo^/IgM− gate contains pro- and pre-B cells, the B220^lo^/IgM+ gate contains immature B cells, and the B220^hi^/IgM+ gate contains mature/recirculating B cells. In the peripheral blood and spleen, we resolved the transitional B-cell compartment using a B220+/IgM+/CD21/35^lo^ gate and the mature/follicular subset using a B220+/IgM+/CD21/35^int^ gate (Fig. [2a](#Fig2){ref-type="fig"}). CD93 is routinely used as an early B-cell developmental marker in non-autoimmune strains of mice (Cancro [@CR4]). In B6 mice, CD93 is expressed at high levels on pro-/pre- and immature B-cell progenitors in the BM (Fig. [2a](#Fig2){ref-type="fig"}). Its expression continues on peripheral blood and splenic TR B cells; albeit at a lower level than that seen on B-cell progenitors in the BM (Fig. [2a](#Fig2){ref-type="fig"}). However, characterization of CD93 expression using the various B-cell developmental subsets in NOD mice revealed a deficiency in its expression by pro-/pre-, immature, and TR B cells in the BM, peripheral blood, and splenic compartments. Overall, cell surface staining of CD93 using the AA4.1 mAb revealed three- to sevenfold reduced expression on the surface of early NOD B-cell progenitors, as compared to their B6 counterparts (Fig. [2a](#Fig2){ref-type="fig"}). CD93 expression on early B-cell subsets of NZB/W F1 mice followed the staining pattern observed in NOD mice (data not shown). Both the absolute number and proportion of CD93+ B cells (i.e., AA4.1+) were significantly reduced in all early B-cell developmental subsets in NOD and NZB/W F1 mice, compared with B6 mice (Fig. [2b](#Fig2){ref-type="fig"}). We utilized three distinct mAbs to quantify the cell surface expression of CD93 in NOD and NZB/W F1 versus B6 mice (Fig. [2c](#Fig2){ref-type="fig"}). AA4.1, 493 and 1696 are known to bind CD93 (McKearn et al. [@CR21]; Rolink et al. [@CR30]). AA4.1, 493 and 1696 staining are deficient in B-cell progenitors of NOD mice as compared to their B6 counterparts (Fig. [2c](#Fig2){ref-type="fig"}). Our inability to detect surface CD93 in NOD and NZB/W F1 mice using anti-CD93 mAbs, despite the presence of CD93 protein expression in BM-derived B-cell precursors and macrophages using polyclonal anti-CD93 antibodies (Fig. [1b](#Fig1){ref-type="fig"}), is likely due to a conformation polymorphism in *Cd93*. Fig. 2CD93 expression and absolute numbers on the various B-cell developmental subsets in BM and peripheral lymphoid organs. **a** The first column divides lymphoid-gated B cells in the bone marrow into mature recirculating (B220^hi^/IgM+), immature (B220^lo^/IgM+), and pro-/pre-B cells (B220^lo^/IgM−). The histograms resolve CD93 expression by AA4.1 antibody on pro-/pre- and immature B cells (*black line*) in contrast with mature recirculating B cells (*dashed line*). The ratio of the mean fluorescence indices (MFIs) of AA4.1 expression by pro-/pre- and immature B cells to the AA4.1 expression by mature recirculating B cells is shown as *MFI fold Δ* on the histograms. Splenic B-cell developmental subsets are divided into the marginal zone (MZ) pool (B220+ gated, IgM^hi^/CD21/35^hi^), FO pool (B220+ gated, IgM^int^/CD21/35^int^), and TR pool (B220+ gated, IgM+/CD21/35^lo^). The histograms display AA4.1 expression by the TR pool (*black line*) in comparison with the FO pool (*dashed line*). The ratio of MFIs of AA4.1 expression by TR B cells and FO B cells is shown as *MFI fold Δ*. B cells in the peripheral blood are divided into the mature recirculating (B220+ gated, IgM+/CD21/35^int^) and the TR pool (B220+ gated, IgM+/CD21/35^lo^). The histograms display AA4.1 expression by the TR pool (*black line*) in comparison with the mature recirculating pool (*dashed line*). The MFI fold Δ is an average of at least *n* = 5 mice per strain shown, and \**p* \< 0.05 compared with B6 mice. **b** The *left panel* shows the total numbers of AA4.1+ pro-/pre- and immature B cells in the BM of B6 (*n* = 12; *black bar*) and NOD (*n* = 10; *white bar*) and NZB/W F1 (*n* = 5, *gray bar*) mice. The *middle panel* shows the total number AA4.1+ TR B cells in the spleen of B6 (*n* = 9; *black bar*), NOD (*n* = 9; *white bar*), and NZB/W F1 (*n* = 5; *gray bar*) mice. The *right panel* shows the percent AA4.1+ cells in the pro-/pre- and immature B cells in the BM and the TR B-cell compartments in the PBL and spleen of B6 (*n* = 12 for BM compartments, *n* = 9 for spleen, *n* = 5 for PBL), NOD (*n* = 10 for BM compartments, *n* = 9 for spleen, *n* = 5 for PBL), and NZB/W F1 (*n* = 5 for all compartments) mice. *Error bars* indicate ± SD, \*\**p* \< 0.01 compared with B6 mice. **c** The *column on the left* shows characteristic AA4.1 expression of B220 cells in the BM of a B6, NOD, and NZB/W F1 mouse. On the *right*, AA4.1 and 493 Abs are used in conjunction on B220+ gated lymphocytes in the BM. The histograms show expression of mAb1696 by pro-/pre- and immature (*black line*) in contrast with mature recirculating (*dashed line*) B cells in the BM of B6, NOD, and NZB/W F1 mice. Staining is representative of at least *n* = 5 per mouse strain

The NOD CD93 defect maps to *Idd13* {#Sec14}
-----------------------------------

The *Cd93* gene maps to 84 cM on murine chromosome 2 (Kim et al. [@CR18]) and falls within the NOD *Idd13* locus (Serreze et al. [@CR32]). *Idd13* congenic B6 and NOD mice were obtained from Jackson Laboratories in order to establish whether these mice carry the B6 or NOD allele. Figure [3a](#Fig3){ref-type="fig"} summarizes the chromosomal regions introgressed from either the B6 or NOD strains onto the NOD and B6 backgrounds for each *Idd13* congenic strain, respectively. The B6.NOD^Idd13^ strain carries the NOD chromosome 2 from 52.5 to 84.2 cM. Early B-cell progenitors from the B6.NOD^Idd13^ strain are deficient in CD93 expression as compared to B6 wild-type counterparts, similarly to NOD wild-type mice (Fig. [3b](#Fig3){ref-type="fig"}). Three NOD.B6^Idd13^ subcongenic mouse lineages (JAX\# 2346, 3050, and 3051) are currently available from Jackson Laboratories (Fig. [3a](#Fig3){ref-type="fig"}). The NOD.B6^Idd13-(D2Mit490-Ada)^ strain harbors B6 chromosome 2 in the range of 64.5--94 cM and, as such, carries the B6 *Cd93* allele (Serreze et al. [@CR32]). Early B-cell progenitors in this strain express CD93 similarly to B6 wild-type counterparts (Fig. [3b](#Fig3){ref-type="fig"}). The NOD.B6^Idd13-(Zfp106-Il1a)^ and NOD.B6^Idd13-(Il1a-Pcna)^ strains harbor B6 chromosome 2 in the range of 67.2--73 and 73--75 cM, respectively (Serreze et al. [@CR32]). Early B-cell progenitors from these *Idd13* subcongenic strains are deficient in CD93 expression as compared to B6 wild-type counterparts, similarly to NOD wild-type mice (Fig. [3b](#Fig3){ref-type="fig"}). Fig. 3The NOD CD93 defect maps to *Idd13*. **a** Chromosomal map showing regions of either NOD chromosome 2 (*white bar*) or B6 chromosome 2 (*black bar*) introgressed onto the B6 or NOD background for each congenic strain obtained from Jackson Laboratories. **b** The *left column* shows AA4.1 staining on B-cell progenitors (B220^lo^) in the BM for each congenic strain. The *middle column* divides B cells in the bone marrow into mature recirculating ( B220^hi^/IgM+), immature (B220^lo^/IgM+), and pro-/pre-B cells (B220^lo^/IgM−) for each of the congenic strains. The histograms resolve AA4.1 expression by pro-/pre- and immature B cells (*black line*) in contrast with mature recirculating B cells (*gray line*). The ratio of the mean fluorescence indices (MFIs) of AA4.1 expression by pro-/pre- and immature B cells to the AA4.1 expression by mature recirculating B cells is shown as *MFI fold Δ*. The MFI fold Δ is an average of at least *n* = 4 mice per strain shown, and \**p* \< 0.05 compared with B6 mice

B6 CD93^−/−^ mice and B6.NOD^Idd13^ mice exhibit a profound state of CD4+ iNKT cell deficiency {#Sec15}
----------------------------------------------------------------------------------------------

The *Cd93* locus maps to a region of chromosome 2, which regulates iNKT cell number and/or function (Chen et al. [@CR5]; Esteban et al. [@CR10]). Therefore, we undertook an analysis of the iNKT cell compartments of B6 CD93^−/−^ (Norsworthy et al. [@CR25]), B6.NOD^Idd13^, and NOD mice. iNKT cells were analyzed in the liver, thymus and spleen using an alpha-GalCer analog, PBS57-loaded CD1d tetramer. iNKT cells were further resolved into CD4+ and CD4− subsets in the spleen and liver and CD4 single positive (CD4SP) and double-negative (DN) subsets in the thymus. Flow cytometric analysis of lymphoid cells in the liver of non-autoimmune B6 mice revealed 15.9 ± 5.79% of the population staining for iNKT cells (Fig. [4a](#Fig4){ref-type="fig"}). In contrast, there was a global deficiency of iNKT cells in lymphoid populations in the livers of B6 CD93^−/−^, B6.NOD^Idd13^, and NOD mice (9.7 ± 4.20%, 7.71 ± 4.29%, and 8.15 ± 3.11%, respectively, *p* \< 0.05 compared with B6 mice, Fig. [4a](#Fig4){ref-type="fig"}). We further resolved the population of iNKT cells into the CD4+ iNKT and CD4− iNKT cell subsets (Fig. [4a](#Fig4){ref-type="fig"}, right column), which allowed us to determine the frequencies of CD4+ iNKT and CD4− iNKT cells in the liver (Fig. [4b](#Fig4){ref-type="fig"}). There is a twofold reduction in the frequency of CD4+ hepatic iNKT cells in B6 CD93^−/−^, B6.NOD^Idd13^, and NOD, compared with B6 mice (*p* \< 0.05, Fig. [4b](#Fig4){ref-type="fig"}). Conversely, the frequency of CD4− iNKT cells in the liver is similar across each of the tested strains of mice (*p* \> 0.05). Figure [4c](#Fig4){ref-type="fig"} shows that the total number of thymic DN and CD4SP iNKT cells is up to twofold less in B6 CD93^−/−^, B6.NOD^Idd13^, and NOD mice, compared with B6 (*p* \< 0.05). Similarly, there is a two- to threefold reduction of total splenic CD4+ iNKT cells in B6 CD93^−/−^, B6.NOD^Idd13^, and NOD compared with B6 mice (*p* \< 0.05), while the CD4− iNKT cell numbers is comparable in all strains of mice tested (*p* \> 0.05, Fig. [4d](#Fig4){ref-type="fig"}). To exclude the possibility that the reduction of CD4+ iNKT cells was due to an overall lymphopenia, we analyzed the total numbers of thymic and splenic lymphocytes and found that the total number of lymphoid cells in B6, B6 CD93^−/−^, B6.NOD^Idd13^, and NOD mice was comparable (*p* \> 0.05, data not shown). Our studies thus confirm that NOD mice possess a CD4+ iNKT cell deficiency (Baxter et al. [@CR1]; Godfrey et al. [@CR14]; Hammond et al. [@CR15]) and show that B6 CD93^−/−^ and B6.NOD^Idd13^ mice exhibit a CD4+ iNKT cell deficiency similar to NOD mice. Fig. 4iNKT cell analysis in B6, B6 CD93^−/−^, B6.NOD^Idd13^ and NOD mice. **a** The *left panel* shows the frequency of iNKT cell staining (CD3^lo^, PBS57-loaded CD1d Tetramer+) in the liver of B6 (*n* = 9, mean 15.9 ± 5.79%) B6 CD93^−/−^ (*n* = 7, mean 9.78 ± 4.20%), B6.NOD^Idd13^, (*n* = 5, mean 7.71 ± 4.29%), and NOD (*n* = 5, mean 8.15 ± 3.11%) mice. The *right panel* further resolves CD4+ iNKT and CD4− iNKT cells. **b** The bar graph indicates the frequency of CD4+ and CD4− iNKT (CD3^lo^, PBS57-loaded CD1d Tetramer+) cells in the livers of B6 CD93^−/−^, B6.NOD^Idd13^, and NOD mice. **c** The bar graph shows the absolute number of thymic DN and CD4SP iNKT cells (CD3^lo^, PBS57-loaded CD1d Tetramer+) in B6, B6 CD93^−/−^, B6.NOD^Idd13^, and NOD mice. **d** The bar graph indicates the total number of splenic CD4+ and CD4− iNKT (CD3^lo^, PBS57-loaded CD1d Tetramer+) cells in B6, B6 CD93^−/−^, B6.NOD^Idd13^, and NOD mice. *Error bars* indicate ± SD, \**p* \< 0.05 compared with B6 mice

Discussion {#Sec16}
==========

In the present study, we identify a hitherto unknown *Cd93* polymorphism in NOD mice. The *Cd93* locus is tightly linked to the diabetes susceptibility gene, *Idd13*, and the Lupus susceptibility loci, *Wbw1* and *Nkt2*, in the region of 82--84 cM on mouse chromosome 2 (Esteban et al. [@CR10]; Jordan et al. [@CR16]; Rahman et al. [@CR29]). Both *Idd13* and *Nkt2* loci have been implicated in regulating the differentiation of natural killer T (NKT) cells, whose relative deficiency in NOD and NZB/W F1 mice is thought to play an important role in the pathogenesis of islet inflammation (Cain et al. [@CR3]; Chen et al. [@CR5]; Duarte et al. [@CR9]; Esteban et al. [@CR10]; Jordan et al. [@CR16]; Matsuki et al. [@CR20]; Poulton et al. [@CR27]; Rahman et al. [@CR29]; Wagner et al. [@CR36]). A subcongenic analysis by Chen et al. revealed that there are at least two genes within *Idd13* that regulate iNKT cell numbers and that NOD mice congenic for the B6 *Idd13* locus were found to be protected from autoimmune diabetes progression associated with normalization of the NOD iNKT cell deficient phenotype (Chen et al. [@CR5]). Our data show that B6.NOD^Idd13^ congenic mice, which carry the NOD *Cd93* allele, are characterized by a deficit in the CD4+ iNKT cell compartment. However, given the large span of chromosomal DNA introgressed into these congenic mice, *Cd93* is only one among many potential candidate genes driving the iNKT cell phenotype. Fletcher et al. have proposed a list of 19 candidate genes, including *Cd93*, within the *Idd13* region, which may be responsible for correcting the NOD NKT cell deficiency. Through construction of NOD mice with a congenic insertion of 12.6 Mb of B6-derived sequence within *Idd13*, the authors show partial correction of the type 1 NKT cell defect in NOD mice (Fletcher et al. [@CR11]). Notably, Fletcher et al. also confirm the genetic location of the *Nkt2* NKT cell control gene to chromosome 2 and provide evidence of the involvement of more than one locus in this region. Given the presence of an NOD and NZB/W F1 specific polymorphism in *Cd93*, we questioned whether this gene might be involved in the regulation of iNKT cell homeostasis. We therefore obtained B6 CD93^−/−^ mice and analyzed their iNKT cell compartments. These analyses revealed a profound deficiency in the CD4+ subset of iNKT cells in CD93^−/−^ mice. It should be noted that the B6 CD93^−/−^ mice were constructed using 129 ES cells. Thus, it remains a possibility that 129 derived alleles within the *Idd13* locus, other than *Cd93*, are identical to their NOD counterparts and cause the observed reduction in CD4+ iNKT cells. In the vicinity of *Cd93* (1 Mb upstream and downstream), 43% of single-nucleotide polymorphisms (SNPs) in NOD and 129 mice are homologous. However, among the homologous SNPs, 84% are also homologous with B6 alleles and can thus be assumed to not contribute to iNKT cell defects (SNP analysis performed via Mouse Genome Informatics; <http://www.informatics.jax.org>). Furthermore, at backcross 7, our CD93^−/−^ mice are 99.22% genetically identical with B6 mice. While we believe it unlikely that there are a significant proportion of remaining 129 derived loci contributing to the observed CD4+ iNKT cell deficit in CD93^−/−^ mice, we acknowledge it as an important caveat.

Several previous reports had noted an overall deficiency in AA4.1 (i.e., CD93) expression in the bone marrow of NOD mice (Langmuir et al. [@CR19]; Quinn et al. [@CR28]; Silveira and Grey [@CR33]). However, these studies did not further elucidate the specific cell populations with the deficit or its basis and functional significance. Here, using three distinct mAbs specific for mouse CD93, we demonstrated a marked defect in the staining pattern of CD93, most prominently visible on early B-cell developmental subsets in the bone marrow. Furthermore, we demonstrated that NZB/W F1 mice exhibited a similar defect in CD93 expression on early B-cell subsets. Despite this aberrant staining pattern observed via flow cytometry, we detected CD93 protein expression using polyclonal antibodies in Western blot assays of BM-derived macrophages or purified B-cell precursors in NOD or NZB/W F1 mice. Moreover, soluble CD93 was detectable in the serum of NOD and NZB/W F1 mice at a level comparable to that seen in non-autoimmune mice. Importantly, deficient CD93 staining using three distinct mAbs was associated with an Asn→His polymorphism at amino acid 264 in NOD and NZB/W F1 mice. This polymorphism falls within the first EGF-like domain of *Cd93*. We believe it likely that this mutation causes a conformational change that renders NOD and NZB/W F1 CD93 virtually undetectable by these monoclonal antibodies.

CD93 was originally isolated and cloned during a search for myeloid surface molecules involved in the enhancement of C1q mediated phagocytosis (Nepomuceno et al. [@CR23]). However, macrophages from CD93-deficient mice are not deficient in their response to C1q. These mice do, however, exhibit an impaired uptake of apoptotic cells in vivo indicating that this receptor contributes to the removal of dying cells (Rolink et al. [@CR30]). In this context, it has been suggested that the priming of autoreactive T and B cells in both autoimmune diabetes and lupus involves an initial response to apoptotic target cells (Turley et al. [@CR35]). Thus, it may be important to determine whether the *Cd93* polymorphism in NOD and NZB/W F1 mice leads to inefficient clearance of apoptotic bodies, thereby setting the stage for the initiation of an autoimmune response. In examining the candidacy of *Cd93* as an *Idd13* candidate gene, it will be important to also consider its recognized role in promoting the uptake of apoptotic cells and immune complexes by antigen presenting cells.

Our recognition of the NOD *Cd93* mutation was a fortuitous outcome of our phenotypic characterization of NOD B-cell development (Quinn et al. [@CR28]). It is well established that CD93 is a marker for early B-cell developmental subsets (Cancro [@CR4]). The relationship between CD93 expression by early B-cell progenitors and iNKT cell homeostasis remains an active area of investigation in our laboratory. Nevertheless, it is possible that expression of this protein on developing B cells plays an independent role in the regulation of B-cell compartment homeostasis. Indeed, it has been shown that mutations within the EGF-like domains of the selectin family members, to which CD93 bears a unique resemblance, inhibit their activity as adhesion molecules (Kansas [@CR17]; Rosen [@CR31]). It will therefore be important to determine whether the NOD polymorphism imparts a defect in immature/TR B-cell migration dynamics as we previously demonstrated (Quinn et al. [@CR28]).

Recently, CD93 expression was shown to be re-induced during plasma cell differentiation from primary B cells (Chevrier et al. [@CR6]). Furthermore, Chevrier et al. suggest that while CD93-deficient mice make normal humoral responses following immunization, they are unable to maintain long-lived plasma cells (LLPC) within the bone-marrow niche (Chevrier et al. [@CR6]). Whether this phenotype is related to the iNKT cell deficiency seen in these mice remains to be determined. Nonetheless, it has been shown that mice lacking iNKT cells cannot sustain antibody responses and LLPC populations (Galli et al. [@CR13]). Therefore, it will be important to determine whether the reliance of LLPC on CD93 is related to their iNKT cell deficient phenotype. Additionally, the CD1 restricted NKT cell specific mitogen alpha-GalCer can induce antibody responses as well as B-cell memory (Galli et al. [@CR13]). iNKT help to B cells can occur without cognate interaction, provided that B cells express the costimulatory molecule, CD40 (Tonti et al. [@CR34]). We are currently investigating the interplay between CD93, iNKT cells, and B cells in both early development and later as they differentiate into LLPCs.

In summary, we describe a coding polymorphism in the first EGF-like domain of *Cd93*. This gene maps to a diabetes susceptibility locus on chromosome 2 and is also tightly linked to the NZB/W F1 *Wbw1* and *Nkt2* disease susceptibility loci, which are thought to regulate NKT cells. Indeed, CD93 deficiency was found to promote a profound state of CD4+ iNKT cell lymphopenia. These data suggest that *Cd93* may be an autoimmune susceptibility gene and may play an important role in regulating the CD4+ iNKT cell compartment. These findings will direct future studies to determine whether *Cd93* is a disease susceptibility gene in NOD and NZB/W F1 mice and whether similar polymorphisms exist in type 1 diabetes or lupus patients.
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BM

:   Bone marrow

TR

:   Transitional

MZ

:   Marginal zone

iNKT cell

:   Invariant natural killer T cell

NOD

:   Non-obese diabetic

DN

:   Double negative

CD4SP

:   CD4 single positive

Idd

:   Insulin-dependent diabetes

alpha-GalCer

:   Alpha-galactosyl ceramide

LLPC

:   Long-lived plasma cell
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